---
marp: true
theme: default
paginate: true
footer: "PHA 548 â€¢ Non-BZD Sedative-Hypnotics â€¢ Hampton University"
style: |
  table { font-size: 20px; }
  .highlight { color: #d35400; font-weight: bold; }
---

# ðŸ§¬ Lecture 02: Medicinal Chemistry of "Z-Drugs"
**Targeting the Î±1-Selective GABA Site**

---

## ðŸŽ¯ High-Yield Learning Objectives
1. **Differentiate** Z-drug pharmacophores from the 1,4-benzodiazepine backbone.
2. **Relate** Î±1-subunit selectivity to clinical outcomes (Sedation vs. Anxiolysis).
3. **Analyze** how "Short & Polar" scaffolds prevent the "Hangover Effect."

---

## ðŸ”¬ The "Z-Drug" Pharmacophore
*Unlike BZDs, Z-drugs do not share a single core, but they occupy the same pocket.*


**Binding Requirements:**
1. **Aromatic/Heteroaromatic ring:** Required for $\pi$-stacking.
2. **H-Bond Acceptor:** Usually a carbonyl or urea group.
3. **Selectivity:** High affinity for **$\alpha_1$ subunits** (Sedation/Amnesia) with low affinity for $\alpha_2/\alpha_3$ (Anxiolysis).

---

## ðŸ’Š Zolpidem (Ambien) - Imidazopyridine
*The most prescribed sedative in the Top 300.*


* **SAR:** The *para*-methyl on the phenyl ring + the imidazopyridine core = **$\alpha_1$ selectivity**.
* **Metabolism:** Rapidly converted to **inactive** metabolites by CYP3A4.
* **Clinical PK:** $t_{1/2} \approx 2.5$ hours. Ideal for **Sleep Onset**.

---

## ðŸ’Š Zaleplon (Sonata) & Eszopiclone (Lunesta)

| Feature | Zaleplon (Pyrazolopyrimidine) | Eszopiclone (Cyclopyrrolone) |
| :--- | :--- | :--- |
| **Structure** | Contains a nitrile group | **(S)-enantiomer** of Zopiclone |
| **Metabolism** | **Aldehyde Oxidase** (Unique!) | CYP3A4 & CYP1A2 |
| **Half-Life** | Ultra-short ($\approx 1$ hour) | Intermediate ($\approx 6$ hours) |
| **Use Case** | Middle-of-night awakening | **Sleep Maintenance** |
| **Side Effect**| Minimal morning grogginess | **Metallic Taste (Dysgeusia)** |

---

## âš ï¸ The "Hangover" SAR Pattern
> **Rule for Boards:** Duration of action is determined by the stability of the scaffold against oxidation.

* **Long-acting (BZD):** Complex rings + active metabolites.
* **Short-acting (Z-drug):** Rapidly oxidized/hydrolyzed + inactive metabolites.

**Active Learning:** Why is Zaleplon preferred for a patient who needs to wake up in 4 hours?
*Answer: Its 1-hour half-life ensures zero receptor occupancy by morning.*
